International prevalence of transthyretin amyloid cardiomyopathy in high-risk patients with heart failure and preserved or mildly reduced ejection fraction

Back

HFA Premium Access

International prevalence of transthyretin amyloid cardiomyopathy in high-risk patients with heart failure and preserved or mildly reduced ejection fraction

Session: Amyloid cardiomyopathy: epidemiology, diagnosis, prognostic and treatment

Topic: Heart Failure with Preserved Ejection Fraction (HFpEF)

Speaker: Doctor S. Yun Viladomat (Hospitalet De Llobregat, ES)

Event: Heart Failure 2024

Congress Presentation

Add to my library

About the speaker

Doctor Sergi Yun Viladomat

Bellvitge University Hospital, Hospitalet De Llobregat (Spain)

1 presentation

0 follower

6 more presentations in this session

Age- and sex-related trends in transthyretin amyloid cardiomyopathy prevalence in older patients with unexplained hypertrophic cardiomyopathy

Speaker: Professor R. Barriales-Villa (Coruna, A, ES)

SGLT2 inhibitor treatment in patients with cardiac amyloidosis

Speaker: Doctor D. Lavall (Leipzig, DE)

Prognostic importance of the 6-minute walk test in transthyretin cardiac amyloidosis

Speaker: Doctor A. Ioannou (Greater London, GB)

Diverse presentations of transthyretin cardiac amyloidosis beyond heart failure with preserved ejection fraction

Speaker: Miss A. Achten (Maastricht, NL)

Cardiac manifestations as precursors to ATTR amyloidosis diagnosis: results from the multi-country OverTTuRe study

Speaker: Doctor K. Jarbrink (Gothenburg, SE)

Access the full session

Amyloid cardiomyopathy: epidemiology, diagnosis, prognostic and treatment

Speakers: Doctor S. Yun Viladomat, Professor R. Barriales-Villa, Doctor D. Lavall, Doctor A. Ioannou, Miss A. Achten...

Access

Video

About the event

Heart Failure 2024

11 May - 14 May 2024

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources